medigraphic.com

2006, Number 4

<< Back Next >>

Arch Cardiol Mex 2006; 76 (4)

Hemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cerebrovascular events

Jerjes-Sánchez DC, Comparan NA, Ibarra FM, Decanini AH, Archondo T

Language: Spanish
References: 32
Page: 366-375
PDF size: 124.75 Kb.


ABSTRACT

Background: In acute coronary syndromes (ACS) interaction among several haemostatic (S and C protein, antitrhombin III, C protein resistance, plasminogen, alpha 2-antiplasmi and inflammatory factors (white cell blood count, fibrinogen, reactive C protein) could have association with recurrent thrombosis and recurrence ischemia, reinfarction, shock and cardiovascular mortality. Methods: Prospective, controlled, with a six-year follow-up trial. End-point: Prove in acute phase and in a follow-up association among inflammatory, coagulation and fibrinolysis markers with cardiovascular adverse events. Inclusion: a) ischemic chest pain at rest › 20 minutes with ST depression or elevation ACS, b) clinical stability. Exclusion: a) › 75 years-old, b) ACS secondary stress, hypertensive crisis, aortic stenosis, c) another acute vascular syndromes suggesting acute ischemia, d) Killip and Kimbal III o IV, e) ejection fraction < 35%, f) pre-hospital treatment with any medication that modify coagulation or fibrinolysis, c) inflammatory acute or chronic process. Control groups: Healthy individuals and stable chronic heart disease patients whose were matched by age and sex. In all patients with ischemic heart disease angiography, nuclear medicine or echocardiography stress tests were done. Statistics: Chi square, student t-test. Lineal, logistic and multivariate regression. Kaplan-Meier and Cox survival curves. Statistical significance: p ‹ 0.05. Results: 50 patients with non- or ST elevation ACS were enrolled. Regression logistic analysis indicated association among plasminogen, antithrombin III and C reactive-protein (p ‹ 0.00001) with death. Protein C and S, protein C resistance and antithrombin III had correlation with death (p 0.0001) and recurrent ischemia (p ‹ 0.0001). Multivariate analysis showed that antithrombin III, plasminogen, C reactive-protein and fibrinogen had significant correlation with death (p 0.001), cardiogenic shock (0.001), new ST-elevation myocardial infarction (0.001). Conclusion: These findings suggesting that in acute phase and in a follow-up of an ACS abnormal coagulation, inflammation and fibrinolysis markers had independent and direct relationship with cardiovascular adverse events.


REFERENCES

  1. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Leo JCW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients wit angina pectoris. N Engl J Med 1995; 332: 635-641.

  2. Center for Disease Control and Prevention: National Center for Health Statistics, National Vital Statistics and The United States Bureau of the Census. Health, United States 1993: 31.

  3. Gersh BJ, Braunwald E, Rutherford JD: Chronic coronary artery disease in “Heart Disease” Eugene Braunwald, Philadelphia Co., WB Saunders Co, 5th Edition 1997: 1289-1365.

  4. Sociedad Mexicana de Cardiología. Guías clínicas para el manejo del infarto agudo del miocardio con elevación del segmento ST. García CA, Jerjes Sánchez C, Martínez SC, LLamas GE, Cardona E, Barragán R, et al, por el Grupo de Trabajo de la Sociedad Mexicana de Cardiología y Asociación Nacional de Cardiólogos de México. Arch Cardiol Mex 2006; 77(Supl 3): S1-S109.

  5. The Task Force on the Management of Acute Myocardial Infarction of the European Cardiology Society: Management of Acute Coronary Syndromes in patients presenting without persistent ST segment elevation. Eur Heart J 2002; 23: 1809-1840.

  6. The Task Force on the Management of Acute Coronary Syndromes of the European Cardiology Society: Management of Acute Myocardial Infarction in patients presenting with ST segment elevation. Eur Heart J 2003; 24: 28-66.

  7. The GUSTO angiographic investigators: The Comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.

  8. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, et al: Loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24: 1602-10.

  9. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139 1147.

  10. Mulvihill NT, Foley B, Murphy R, Crean P, Walsh M: Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 2000; 36: 1210-1216.

  11. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, et al: Thrombogenic factors and recurrent coronary events. Circulation 1999: 2517-2522.

  12. Kennon S, Price CP, Mills PG, Ranjadayalan K, Cooper J, Clarke H, et al: The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001; 37: 1266 1270.

  13. Comparan A, Palacios JM, Jerjes Sánchez C: Leucocitos y su asociación con eventos cardiovasculares adversos en infarto con elevación del ST llevados a intervención coronaria percutánea. Arch Cardiol Mex 2005; 75(Supl 3): S91-S98.

  14. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G: The TIMI risk score for unstable angina/non-ST elevation MI. JAMA 2000; 284: 835-841.

  15. O’Rourke RA, Hochman JS, Cohen MC, Lucore CHL, Popma JP, Cannon CP: New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction. Arch Intern Med 2001; 161: 674-682.

  16. Morrow DA, Antman EM, Tanasijevic M, Rifai N, Lemos JA, McCabe CH, et al: Cardiac troponin I for stratification of early outcomes and efficacy of enoxaparin in unstable angina. A TIMI – 11B substudy. J Am Coll Cardiol 2000; 36: 1812-1817.

  17. Hamm CW, Braunwalds E: A classification of unstable angina revisited. Circulation 2000; 102: 118-122.

  18. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-1182.

  19. Lip GYH, Blan ADD: Thrombogenesis and fibrinolysis in acute coronary ischemic syndromes. J Am Coll Cardiol 2000; 36: 2044-2046.

  20. Iftikhar K, Gerald G, Jamil TA: Novel risk factor for atherosclerosis. Mayo Clin Proc 2000; 75: 369-380.

  21. Canseco ALM, Ortiz LR, Rojas MA, Guzmán RD, Jerjes SC: Fibrinógeno ¿Factor o indicador de riesgo cardiovascular? Arch Cardiol Mex 2006. En prensa.

  22. Figueras JM, Monasterio Y, Lidón RM, Nieto E, Soler-Soler J: Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest. J Am Coll Cardiol 2000; 36: 2036-2043.

  23. Schafer AI: Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739-1742.

  24. Macaulay O: Inherited thrombophilia, hypercoagulability and risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 870-871.

  25. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T, et al: Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res 1999; 94: 69-78.

  26. Evans SM, Brittenden J, Adam DJ, Ludlam C, Bradbury AW: Prevalence and significance of thrombophilia in patients with intermittent claudication. Br J Surg 1999; 86: 702-703.

  27. Strater R, Vielhaver H, Kassenbohmer R, von Kries R, Gobel U, Nowak-Gottel U: Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin: a prospective ESPED survey. Eur Pediatr 1999; 158 (Suppl 3): S122-S125.

  28. Koh S, Chen LS: Protein C deficiency in children with ischemic cerebrovascular accident. Pediatr Neurol 1997; 319: 319-321.

  29. Brown NJ, Vaughan DE: The renin-angiotensin and fibrinolytic systems. Trends Cardiovasc Med 1996; 6: 239-243.

  30. Wannamethee SG, Lowen GDO, Shaper AG, Rumley A, Lennon L, Whincup PH: Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005; 26: 1765-1773.

  31. Lerman A, Zeiher AM: Endothelial function and cardiac events. Circulation 2005; 111; 363-368.

  32. Jerjes SC: Venous and arterial thrombosis. A continuum spectrum of the same disease? Eur Heart J 2005; 26: 1-2.




2020     |     www.medigraphic.com